SPY334.19+5.46 1.66%
DIA275.90+4.20 1.55%
IXIC11,117.53+203.96 1.87%

Immunovant shares are trading higher after the company announced the results from its multi-center, placebo-controlled Phase 2a trial of IMVT-1401 were statistically significant.

Benzinga · 08/25/2020 13:21